Business Wire

Data of Chugai's Alecensa® Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the results of the global phase III study (the ALEX study) of Alecensa®, conducted by F. Hoffmann-La Roche Ltd., in ALK fusion gene positive non-small cell lung cancer (NSCLC) patients, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago. The presentation will be held on oral abstract sessions on 6th June (Tue) 12:09-12:21 (CDT) as a late breaking subject.

Abstract LBA9008
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

“In the ALEX study comparing the efficacy and safety of first line therapy of Alecensa with crizotinib, Alecensa showed a significant prolongation of PFS and reduced the risk of disease progression by 84% in patients with brain metastasis. The study also showed that Alecensa was well tolerated. These results will encourage the patients to fight cancer,” said Dr. Yasushi Ito, Senior Vice President, Head of Project & Lifecycle Management Unit. “We believe that Alecensa will also contribute to improving the outcomes of many ALK fusion gene positive NSCLC patients not just in Japanese but overseas.”

The ALEX study was an open-label, randomized global phase III study that compares the efficacy and safety between Alecensa and crizotinib in the first line therapy. The ALEX study enrolled treatment-naïve 303 patients with ALK fusion gene positive NSCLC. The subjects were allocated to either the Alecensa arm or the crizotinib arm in a one to one ratio. The primary endpoint of the ALEX study was PFS as assessed by the investigator. The secondary endpoints included independent review committee (IRC)-assessed PFS, IRC-assessed time to CNS progression, objective response rate, overall survival, safety and other endpoints.

Summaries of the ALEX study results
Efficacy:

- At the primary data cut-off, Alecensa arm demonstrated statistically significant improvement superiority vs crizotinib arm, reducing risk of progression or death by 53% (HR=0.47, 95%CI: 0.34-0.65, stratified log-rank test, p<0.0001) by investigators’ assessment. Median PFS was not reached (95%CI: 17.7-not reached) in the Alecensa arm while it was 11.1 months (95%CI: 9.1-13.1) in the crizotinib arm.

- According to independent review committee, Alecensa arm demonstrated statistically significant improvement superiority vs crizotinib arm, reducing risk of progression or death by 50% (HR=0.50, 95%CI: 0.36-0.70). Median PFS was 25.7 months (95%CI: 19.9-not reached) in the Alecensa arm while it was 10.4 months (95%CI: 7.7-14.6) in the crizotinib arm.

- Alecensa arm demonstrated improvement vs crizotinib arm, reducing risk of CNS progression or death by 84% (HR=0.16, 95% CI: 0.10-0.28).

- Overall survival data are currently considered immature with only about a quarter of events being reported.

Safety:

- Grade 3-5 adverse events (AEs) were less frequent with Alecensa arm, 41%, vs 50% with crizotinib arm.

- No new safety findings were observed in either arm.

About Alecensa

Alecensa is a highly selective oral ALK inhibitor created by Chugai. It has been reported that approximately five percent of patients with NSCLC express a chromosomal rearrangement which leads to fusion of the ALK gene with another gene.1) ALK kinase signalling is constantly active in cells with such fusion genes, resulting in uncontrolled growth of tumour cells and transforming the cells into tumour cells. 2, 3) Alecensa exerts its anti-tumour effect by selectively inhibiting ALK kinase activity to inhibit tumour cell proliferation and induce cell death. 4) In addition, Alecensa is not recognized by the active efflux system in the blood brain barrier which actively pumps molecules out of the brain. Thus, Alecensa is able to remain active in the central nervous system and has proven activity against brain metastases.

Alecensa is currently approved in the United States, Kuwait, Israel, Hong Kong, Canada, South Korea, Switzerland, India, the EU, Australia, Taiwan and Singapore for the treatment of adult patients with ALK-positive, metastatic (advanced) NSCLC who have progressed on or those intolerant to crizotinib. In Japan, “Alecensa capsule 150mg” is available to patients with “ALK fusion gene positive unresectable, recurrent/advanced NSCLC” and is marketed by Chugai.

The approved dosage and administration in Japan is “300mg alectinib is administered orally twice daily for adult patient.”

1) Biomarker committee of The Japan Lung Cancer Society, Guidelines for ALK gene tests in lung cancer patients
2) Soda et al., Nature. 448: 561-566 (2007)
3) Takeuchi et al., Clin Cancer Res. 15: 3143-3149 (2009)
4) Sakamoto et al., Cancer Cell. 19: 679-690 (2011)

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totalled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Trump International Hotel Washington, D.C. Announced as First Forbes Five Star Hotel in Downtown Washington, D.C.22.2.2018 19:21Pressemelding

Trump International Hotel Washington, D.C. announces today that it has been awarded the 2018 Forbes Five-Star recognition, making it the first hotel to receive the prestigious distinction in Downtown Washington D.C. Forbes Travel Guide, the global authority on luxury travel, sends anonymous professional inspectors around the world to assess hotels, restaurants and spas against up to 800 objective standards focused on service and facilities. Just opened a short fifteen months ago, the property is located on Pennsylvania Avenue in the center of the city at the site of the Old Post Office. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006277/en/ Trump International Hotel Washington, D.C. (Photo: Business Wire) Mickael Damelincourt, Managing Director, oversaw the recruitment and selection of the executives whose teams would lead the hotel through the construction and opening phases, instilling a commitment to the highest l

Entrust Datacard and Infineon Partner to Reduce Complexities with Securing IoT Deployments22.2.2018 18:30Pressemelding

Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced it has joined the Infineon Security Partner Network (ISPN). The ISPN is part of Infineon Technologies AG, a leading provider of semiconductor solutions used in automotive, industrial, computing and Internet of Things applications. The ISPN is composed of associated and preferred security partners who are proven experts in security consulting, security solution provisioning, electronic design, systems integration and trust services management. The new partnership will apply the Entrust Datacard™ ioTrust™ Security Solution that uses identity-based technology to help securely connect the people, applications and devices that power the connected world. The tiered software uses sophisticated cryptographic technology to provide identity issuance, management and data security of connected things within industrial environments. As a global leader in Trusted Platform Modules (TP

Blue Danube Systems Joins xRAN Forum as a Massive MIMO System Supplier Fully Committed to Open Interfaces22.2.2018 18:10Pressemelding

Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced that it has joined the xRAN Forum (www.xran.org). The xRAN Forum was formed by several leading global mobile operators to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN (Radio Access Network) architecture. Massive MIMO systems are widely recognized to be a critical element of future 5G wireless networks. Blue Danube’s unique approach to Massive MIMO, based on the company’s underlying High Definition Active Antenna Systems (HDAAS™) technology, not only delivers capacity gains in existing LTE networks with today’s smartphones but also enables intelligent analytics-based RF virtualization for multi-site network performance optimization. Blue Danube’s first Massive MIMO product, the BeamCraft™ 500, has been deployed at four FDD-LTE operators to date, interfacing to four diffe

Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments22.2.2018 18:07Pressemelding

Blue Danube Systems, a provider of intelligent wireless access solutions that help mobile operators address the challenge of explosive data growth, today announced it has successfully expanded the commercial deployment of its massive MIMO solution to multiple clustered cell sites, demonstrating total capacity improvements for directly adjoining sectors on existing LTE networks using current smartphones. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006158/en/ Blue Danube Systems First to Demonstrate Benefits of FDD Massive MIMO in Clustered Multi-Sector Deployments (Photo: Business Wire) Despite the prevalent view that Massive MIMO systems will be central to 5G networks, it has not been clearly proven that the technology is deployable beyond isolated high-demand sectors where effects such as adjacent cell interference must be addressed. In fact, common digital-only Massive MIMO implementations typically operate as clos

Avnet and IDEMIA Develop Highly Flexible ‘Plug & Play’ Cellular Connectivity Solution for IoT and Industry 4.0 Applications22.2.2018 16:08Pressemelding

Avnet (NYSE: AVT), a leading global technology distributor and IDEMIA (formerly known as OT-Morpho), the global leader in Augmented Identity, have joined forces to collaborate on the development of a new future-proof cellular connectivity solution that meets the growing communication requirements for Internet of Things (IoT) and Industry 4.0 applications. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005966/en/ (Photo: IDEMIA) The new ‘plug & play’ eUICC (embedded Universal Integrated Circuit Card) and SM-SR (Subscription Management Secure Routing) delivers product future-proofing capability to IoT application solution providers and other businesses. It provides them with the ability to easily choose a mobile network operator (MNO) without eventually having to manually change the embedded SIM card in their cellular connectivity-based devices, machines and sensors that are already deployed in the field. The product bund

TINE Boosts Logistics Performance with Quintiq’s Route Optimization Technology22.2.2018 15:41Pressemelding

Quintiq, a Dassault Systèmes company and global leader in supply chain planning and optimization (SCP&O), announced that its tactical planning solution for TINE AS has resulted in more cost-effective routes. Given the success of this project, the leading Norwegian dairy producer is now embarking on a second phase to further enhance its tactical planning and expand the solution’s scope to include operational planning. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005936/en/ TINE goes further with optimized logistics. Credit: Bo Mathisen Last year, TINE went live with the first phase of the Quintiq solution, designed to optimize the company’s last-mile delivery of dairy products on a tactical level. TINE’s planners used Quintiq to plan shipment routes from central distribution centers all over Norway to customers. They were able to manage the complexity of trailer swapping, various types of resources, dynamic time window